Description
The field of cancer rehabilitation continues to evolve, creating diverse opportunities for physiatrists to build sustainable and impactful practices. This session will explore various business models in cancer rehabilitation, featuring insights from established practitioners from across the country. Panelists will discuss key aspects of different practice settings, including academic institutions, private practice, hospital-based models, hybrid structures, and procedural-based approaches. Designed for medical students, residents, and early-career physiatrists, this discussion will provide valuable perspectives on job prospects, practice management, and financial considerations in cancer rehabilitation. Attendees will gain a deeper understanding of the opportunities available in this growing field, the challenges associated with different business models, and strategies for career success.

Learning Objectives
Learning Objective 1: Compare and contrast different business models of cancer rehabilitation practices, including private practice, academic, hospital-based, hybrid, and procedural-based models.
Learning Objective 2: Identify key financial, administrative, and operational considerations for establishing or joining a cancer rehabilitation practice.
Learning Objective 3: Understand job market trends and employment opportunities in cancer rehabilitation.
Learning Objective 4: Evaluate potential career paths based on personal and professional goals.
Learning Objective 5: Develop strategies for integrating procedural interventions into cancer rehabilitation practice.

Member Community
Cancer Rehabilitation Medicine

Faculty
Session Directore: Leslie Bagay, MD, DO, FAAPMR: Disclosed no relevant financial relationships.       
Lisa Ruppert, MD, FAAPMR, Advisory for Ipsen.   
Michael Stubblefield, MD, FAAPMR: Scientific Advisory/Speaker for Tactile Medical.
Kelsey Lau, DO, FAAPMPR: Disclosed no relevant financial relationships.    
Jessica Cheng, MD, FAAPMR: Disclosed no relevant financial relationships.    
Diana Molinares,MD, FAAPMR Disclosed no relevant financial relationships

AAPM&R Medical Education Committee
John C. Cianca, MD: Ownership or partnership with Musculoskeletal Ultrasound Consultants, LLC.
Karen P. Barr, MD: Disclosed no relevant financial relationships.
Rachel A. Brakke Holman, MD: Disclosed no relevant financial relationships.
Joseph E. Burris, MD: Serves on the Speakers Bureau for, and received clinical research grants from Allergan.
David S. Cheng, MD: Disclosed no relevant financial relationships.
Theresa A. Gillis, MD: Disclosed no relevant financial relationships.
Kevin N. Hakimi, MD: Disclosed no relevant financial relationships.
Matthew T. Haas, MD: Disclosed no relevant financial relationships.
R.Samuel Mayer, MD: Royalties from Demos Medical Publishing.
Ameet S. Nagpal, MD MS MEd: Disclosed no relevant financial relationships.
Sunil Sabharwal, MD: Royalities from Demos Publishing; board member, American Board of Physical Medicine and Rehabilitation.
Sarah M. Smith, MD: Disclosed no relevant financial relationships.
Stephanie Tow, MD: Disclosed no relevant financial relationships.
Kevin R. VIncent, MD, PhD: Disclosed no relevant financial relationships.

AAPM&R CME Committee
Karen P. Barr, MD: Disclosed no relevant financial relationships.
Cherry C. Junn, MD: Disclosed no relevant financial relationships.
Sheryl R. Levin, MD: Disclosed no relevant financial relationships.
Kentaro Onishi, DO: Disclosed no relevant financial relationships.
Evan R. Peck, MD: Disclosed no relevant financial relationships.
Cynthia G. Pineda, MD: Disclosed no relevant financial relationships.
Patricia T. Tan, MD: Disclosed no relevant financial relationships.
Brionn K. Tonkin, MD: Disclosed no relevant financial relationships.
Kristin A. Wong, MD: Disclosed no relevant financial relationships.

No other planners, faculty or other individuals in control of content disclosed any relevant financial relationships.

FDA Disclosures
All faculty members for this activity have disclosed they do not intend to discuss or demonstrate any pharmaceutical or medical device for which FDA clearance has not been approved.